| Redirecting T cells to hematological malignancies with bispecific antibodies MP Velasquez, CL Bonifant, S Gottschalk Blood, The Journal of the American Society of Hematology 131 (1), 30-38, 2018 | 163 | 2018 |
| Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity B Prinzing, CC Zebley, CT Petersen, Y Fan, AA Anido, Z Yi, P Nguyen, ... Science translational medicine 13 (620), eabh0272, 2021 | 161 | 2021 |
| Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells K Iwahori, S Kakarla, MP Velasquez, F Yu, Z Yi, C Gerken, XT Song, ... Molecular Therapy 23 (1), 171-178, 2015 | 99 | 2015 |
| CD123-engager T cells as a novel immunotherapeutic for acute myeloid leukemia CL Bonifant, A Szoor, D Torres, N Joseph, MP Velasquez, K Iwahori, ... Molecular Therapy 24 (9), 1615-1626, 2016 | 85 | 2016 |
| A bump in the road: how the hostile AML microenvironment affects CAR T cell therapy R Epperly, S Gottschalk, MP Velasquez Frontiers in oncology 10, 262, 2020 | 66 | 2020 |
| T cells expressing CD19-specific engager molecules for the immunotherapy of CD19-positive malignancies MP Velasquez, D Torres, K Iwahori, S Kakarla, C Arber, T Rodriguez-Cruz, ... Scientific reports 6 (1), 27130, 2016 | 62 | 2016 |
| Erythrocytapheresis in children with sickle cell disease and acute chest syndrome MP Velasquez, MM Mariscalco, SL Goldstein, GE Airewele Pediatric Blood & Cancer 53 (6), 1060-1063, 2009 | 57 | 2009 |
| CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells N Hebbar, R Epperly, A Vaidya, U Thanekar, SE Moore, M Umeda, J Ma, ... Nature Communications 13 (1), 587, 2022 | 52 | 2022 |
| Improving care for children with sickle cell disease/acute chest syndrome EA Crabtree, MM Mariscalco, J Hesselgrave, SF Iniguez, TJ Hilliard, ... Pediatrics 127 (2), e480-e488, 2011 | 42 | 2011 |
| CD28 and 41BB costimulation enhances the effector function of CD19-specific engager T cells MP Velasquez, A Szoor, A Vaidya, A Thakkar, P Nguyen, MF Wu, H Liu, ... Cancer immunology research 5 (10), 860-870, 2017 | 36 | 2017 |
| T cell-activating mesenchymal stem cells as a biotherapeutic for HCC A Szoor, A Vaidya, MP Velasquez, Z Mei, DL Galvan, D Torres, A Gee, ... Molecular Therapy-Oncolytics 6, 69-79, 2017 | 35 | 2017 |
| Engineering naturally occurring CD7− T cells for the immunotherapy of hematological malignancies A Freiwan, JT Zoine, JC Crawford, A Vaidya, SA Schattgen, JA Myers, ... Blood, The Journal of the American Society of Hematology 140 (25), 2684-2696, 2022 | 34 | 2022 |
| Common trajectories of highly effective CD19-specific CAR T cells identified by endogenous T-cell receptor lineages TL Wilson, H Kim, CH Chou, D Langfitt, RC Mettelman, AA Minervina, ... Cancer discovery 12 (9), 2098-2119, 2022 | 31 | 2022 |
| Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL AC Talleur, A Qudeimat, JY Metais, D Langfitt, E Mamcarz, JC Crawford, ... Blood Advances 6 (21), 5737-5749, 2022 | 26 | 2022 |
| The art and science of selecting a CD123-specific chimeric antigen receptor for clinical testing JM Riberdy, S Zhou, F Zheng, YI Kim, J Moore, A Vaidya, RE Throm, ... Molecular Therapy Methods & Clinical Development 18, 571-581, 2020 | 21 | 2020 |
| Harnessing T cells to target pediatric acute myeloid leukemia: CARs, BiTEs, and beyond R Epperly, S Gottschalk, MP Velasquez Children 7 (2), 14, 2020 | 21 | 2020 |
| Engager cells for immunotherapy SMG Gottschalk, XT Song, K Iwahori, MP Velasquez, S Abbot US Patent App. 14/773,327, 2016 | 18 | 2016 |
| Safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML: preliminary results from a phase 1 trial S Naik, RM Madden, A Lipsitt, T Lockey, J Bran, JE Rubnitz, J Klco, ... Blood 140 (Supplement 1), 4584-4585, 2022 | 17 | 2022 |
| Advances in immunotherapy for pediatric acute myeloid leukemia CL Bonifant, MP Velasquez, S Gottschalk Expert Opinion on Biological Therapy 18 (1), 51-63, 2018 | 16 | 2018 |
| Targeting CD19: the good, the bad, and CD81 MP Velasquez, S Gottschalk Blood, The Journal of the American Society of Hematology 129 (1), 9-10, 2017 | 13 | 2017 |
Stephen GottschalkSt Jude Children's Research Hosptial在 stjude.org 的电子邮件经过验证
